Across TCGA pan-cancer cohorts, CDK5R2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CDK5R2 data layer compared with 26 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher CDK5R2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDK5R2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where CDK5R2 mass-spec protein most reproducibly stratifies survival.